Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium
Takemura K, Navani V, Ernst M, Wells J, Meza L, Pal S, Lee J, Li H, Agarwal N, Alva A, Hansen A, Basappa N, Szabados B, Powles T, Tran B, Hocking C, Beuselinck B, Yuasa T, Choueiri T, Heng D. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Journal Of Urology 2022, 209: 701-709. PMID: 36573926, DOI: 10.1097/ju.0000000000003132.Peer-Reviewed Original ResearchConceptsTKI cohortInternational Metastatic Renal Cell Carcinoma Database ConsortiumComplete responseFirst-line therapyOverall survivalCombination therapyTKI armsTyrosine kinase inhibitor therapyMetastatic renal cell carcinomaNon-clear cell histologyMultiple sites of metastasesTyrosine kinase inhibitor monotherapyBaseline characteristics of patientsResponse rateComplete response rateKinase inhibitor therapyOverall survival benefitSite of metastasisFavorable overall survivalRenal cell carcinomaAdverse clinicopathological featuresCharacterization of patientsReal-world patientsCharacteristics of patientsClinical trial populationsFirst-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Roussel E, Kinget L, Beuselinck B, Albersen M, Wells C, Ernst M, Donskov F, Schmidt A, Szabados B, Pal S, Meza L, Agarwal N, Weickhardt A, Davis I, Alva A, Wood L, Porta C, Choueiri T, Heng D, Navani V. First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 317-317. DOI: 10.1200/jco.2022.40.6_suppl.317.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumMetastatic renal cell carcinomaPancreatic metastasisOverall survivalVascular endothelial growth factorRenal cell carcinomaMedian OSCell carcinomaInternational Metastatic Renal Cell Carcinoma Database Consortium risk groupMetastatic renal cell carcinoma patientsMedian OS of patientsRetrospective analysis of patientsEfficacy of first-lineKaplan Meier survival curvesOS of patientsSite of metastasisFirst-line therapyAssociated with improved outcomesIndolent biological behaviorAnalysis of patientsAnti-angiogenic therapyVEGF monotherapyEndothelial growth factorLow event ratesImproved OS